Sorrento Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. The company traces its roots to 2006, when it was originally incorporated in California as San Diego Antibody Company, before adopting the Sorrento Therapeutics name and reincorporating in Delaware in 2009. Its historical headquarters and principal operating base have been in San Diego, California, which has remained central to its corporate identity and life-sciences footprint.([sec.gov](https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm?utm_source=openai)) Sorrento has long positioned itself as an antibody-centric, clinical-stage and commercial-stage biotech focused on innovative therapies for high-unmet-need indications. Its core R&D strategy has revolved around proprietary platforms such as the G-MAB™ fully human antibody library, targeted delivery modalities, immuno-cellular therapies including DAR-T™ and CAR-T concepts, antibody-drug conjugates (ADCs), and oncolytic virus programs such as Seprehvec™. Over time, the company has also discussed pipeline efforts in cancer, pain, autoimmune disease, infectious disease, and coronavirus-related programs, including diagnostic and antiviral initiatives. That breadth gives Sorrento scientific optionality, but it also reflects the complexity and execution risk of a platform-driven biotech model.([sec.gov](https://www.sec.gov/Archives/edgar/data/850261/000156459021006983/srne-10k_20201231.htm?utm_source=openai)) From a competitive standpoint, Sorrento operates in one of the most crowded and capital-intensive segments of healthcare. Its differentiation has historically been based on combining multiple therapeutic modalities rather than relying on a single lead asset. However, the company’s recent history has been dominated by restructuring rather than product commercialization. A key recent development was the September 2023 sale of substantially all Scilex securities held by Sorrento; following that transaction, Sorrento no longer controlled Scilex, and Scilex was deconsolidated from Sorrento’s financial statements as discontinued operations. The transaction also took place in the context of Sorrento’s Chapter 11 proceedings, underscoring that the equity story is closely tied to balance-sheet repair, asset monetization, and legal restructuring.([sec.gov](https://www.sec.gov/Archives/edgar/data/850261/000110465923103911/tm2326887d1_ex99-2.htm)) Geographically, Sorrento’s presence is primarily U.S.-centric, with its operational and historical base in California. For investors in France, Belgium, and Switzerland, SRNE should therefore be viewed as a special-situation healthcare name on the NASDAQ, not a stable dividend payer or mature pharma franchise. The investment case is driven by binary clinical/regulatory outcomes, restructuring milestones, and potential value realization from legacy assets. In short, Sorrento is a highly speculative U.S. biotech with a broad scientific platform, a long development history, and a recent corporate narrative shaped by deconsolidation, bankruptcy proceedings, and asset rationalization.([sec.gov](https://www.sec.gov/Archives/edgar/data/850261/000095017023008238/srne-20221231.htm?utm_source=openai))